FDA taps chemora­dio-sen­si­tiz­ing head and neck can­cer drug as 'break­through'

Years af­ter a fam­i­ly of en­doge­nous pro­teins known as IAP, or in­hibitors of apop­to­sis pro­teins, was first linked to poor prog­no­sis of can­cer, the FDA is help­ing move along a drug that blocks it.

De­bio­pharm’s De­bio 1143 now en­joys break­through sta­tus at the agency, af­ter Phase II re­sults un­veiled at ES­MO sug­gest­ed that adding it to a reg­i­men of chemora­di­a­tion ther­a­py boost­ed lo­core­gion­al con­trol rate as well as pro­gres­sion-free sur­vival among pa­tients with “high risk” lo­cal­ly ad­vanced squa­mous cell car­ci­no­ma of the head and neck.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.